CEO Message to Shareholders

Released: July 1, 2009

This is an exciting time in the growth of our company and today marks yet another important milestone in the company’s 18-year history.

As you are aware, the spin-off of Myriad Pharmaceuticals from Myriad Genetics was completed yesterday, creating two well-capitalized, highly-focused, independent public companies. The separation of these two organizations should enable each company to more readily pursue its strategic initiatives and compete more effectively in its respective market. As a result, we believe the spin-off transaction will help build increased shareholder value over the long-term.

Myriad Pharmaceuticals, which trades on the Nasdaq Global Market under the ticker symbol “MYRX,” now comprises our former research and drug development businesses. The company is focused on discovering, developing, and commercializing novel small molecule drugs that address severe medical conditions, including cancer and HIV infection. The company has three principal drug candidates in human clinical trials – Azixa™, MPC-4326 and MPC-3100. More information may be found at www.myriadpharma.com.

Myriad Genetics, which will continue to trade on the Nasdaq Global Select Market under the ticker symbol “MYGN,” is focused on developing and marketing novel molecular diagnostic products. We were early pioneers in the exciting and fast growing field of predictive and personalized medicine, and we are continually striving to remain as the global leader in molecular diagnostics. Myriad currently has seven marketed products that provide physicians with critical information to better manage their patients’ healthcare – BRACAnalysis® (breast and ovarian cancer predisposition); COLARIS® (colorectal and uterine cancer predisposition); COLARIS AP® (colon polyp forming syndrome predisposition); MELARIS® (melanoma predisposition); TheraGuide® 5-FU (chemotherapy selection); PREZEON™ (chemotherapy selection); and OnDose™ (chemotherapy dosing).

The Myriad Genetics team is hard at work expanding the adoption of our current products, while developing and launching new products to drive our future success. We look forward to keeping you apprised of our continued progress and welcome you to this new chapter in the evolution of Myriad Genetics.

Peter D. Meldrum
President and CEO